Open AccessProtocolos terapêuticos para cães com hemangiosarcoma esplênico – revisão sistemática
Author(s) -
Bárbara Rocha Pereira,
Centro Universitário Luterano de Palmas,
Caio Vitor Bueno Dias,
A. L. S. Guimarães
Publication year - 2021
Publication title -
revista agrária acadêmica
Language(s) - English
Resource type - Journals
ISSN - 2595-3125
DOI - 10.32406/v4n6/2021/3-12/agrariacad
Subject(s) - hemangiosarcoma , medicine , cyclophosphamide , vincristine , stage (stratigraphy) , chemotherapy , oncology , pathology , angiosarcoma , biology , paleontology
Hemangiosarcoma is a malignant and aggressive tumor composed of pleomorphic endothelial cells filled with blood and solid cell agglomerations. This tumor has a larger sample in dogs, especially the elderly aged 8 to 13 years. The aim of this systematic review is to understand and evaluate therapeutic protocols for dogs with splenic hemangiosarcoma. To this end, articles published from 2010 to 2020 were searched in the PubMed database, covering national and international publications. In total, 7 references were selected by the established criteria. The results of this literature review report that the clinical stage is strongly associated with the survival time of dogs with splenic hemangiosarcoma. Chemotherapy treatment is effective in increasing survival time during the early stage of the disease follow-up period. Combinations of conventional protocols containing doxorubicin and metronomic protocols containing cyclophosphamide were performed to have the greatest efficacy, but prolongations in survival time were modest. Future research should target specific protocols for animals with specific comorbidities and so far no studies have been registered that distinguish a treatment for males and females with splenic hemangiosarcoma.